NEW YORK, NY / ACCESSWIRE / August 3, 2022 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.
Apyx Medical Corporation (NASDAQ:APYX)
CONTACT JAKUBOWITZ ABOUT APYX:
https://claimyourloss.com/securities/apyx-medical-corporation-loss-submission-form/?id=30528&from=1
Class Period : May 12, 2021 - March 11, 2022
Lead Plaintiff Deadline : August 5, 2022
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) a significant number of Apyx's Advanced Energy products were used for off-label indications; (2) such off-label uses led to an increase in the number of medical device reports filed by Apyx reporting serious adverse events; (3) as a result, the Company was reasonably likely to incur regulatory scrutiny; (4) as a result of the foregoing, the Company's financial results would be adversely impacted; and (5) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Digital Turbine, Inc. (NASDAQ:APPS)
CONTACT JAKUBOWITZ ABOUT APPS:
https://claimyourloss.com/securities/digital-turbine-inc-loss-submission-form/?id=30528&from=1
Class Period : February 26, 2021 - May 31, 2022
Lead Plaintiff Deadline : August 5, 2022
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the Company's recent acquisitions, AdColony and Fyber, act as agents in certain of their respective product lines; (2) as a result, revenues for those product lines must be reported net of license fees and revenue share, rather than on a gross basis; (3) the Company's internal control over financial reporting as to revenue recognition was deficient; and (4) as a result of the foregoing, the Company's net revenues was overstated throughout fiscal 2022; and (5) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Verrica Pharmaceuticals, Inc. (NASDAQ:VRCA)
CONTACT JAKUBOWITZ ABOUT VRCA:
https://claimyourloss.com/securities/verrica-pharmaceuticals-inc-loss-submission-form/?id=30528&from=1
Class Period : May 28, 2021 - May 24, 2022
Lead Plaintiff Deadline : August 5, 2022
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) there were manufacturing deficiencies at the facility where Verrica's contract manufacturer produced a bulk solution for the Company's lead product candidate, VP-102; (2) these deficiencies were not remediated when Verrica resubmitted its New Drug Application for VP-12 for molluscum; (3) the foregoing presented significant risks to Verrica obtaining regulatory approval of VP-102 for molluscum; and (4) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
SOURCE : Jakubowitz Law